The CardiAMP Heart Failure II Trial is a study aimed at helping people with ischemic heart failure, a condition where the heart doesn't pump blood as well as it should due to reduced ejection fraction. This study uses a treatment called **CardiAMP cell therapy**, which involves using special cells from your own bone marrow, called **mononuclear cells (MNCs)**, that may help improve heart function. The study will compare this treatment to a standard procedure called **diagnostic catheterization**, which is a test to see how well your heart is working. This is a **prospective, multi-center, randomized, controlled, patient and evaluator-blinded study**, which means it’s conducted at multiple locations, and neither the patients nor the doctors know who receives the actual treatment or the control procedure.

• Participants will be randomly assigned to receive either the CardiAMP treatment or the control procedure.
• The study is blinded, meaning neither you nor the doctors will know which treatment you receive.
• Your heart function and health will be closely monitored throughout the study.

To join, you need to have certain heart conditions and meet specific health criteria. This study aims to find new ways to help people with heart failure.